Address
Sector 14, Road no. 18, Uttara, 1230
Dhaka, Bangladesh
Rx Prescripttion Only-YMYL Medical Content
Caboxen 20 mg
Cabozantinib 20mg capsules – Everest Pharmaceuticals Ltd.
Approved for BRCA-mutated ovarian, fallopian tube, or primary peritoneal cancer (maintenance treatment after platinum-based chemotherapy), BRCA-mutated HER2-negative metastatic breast cancer, BRCA-mutated metastatic pancreatic cancer (maintenance after platinum chemotherapy), and BRCA or HRR-gene-mutated metastatic castration-resistant prostate cancer.
- Clinical outcomes at a glance
11.2 mo
Median PFS vs 4.0 months with placebo in metastatic medullary thyroid cancer (EXAM trial, HR 0.28)
METEOR
Improved OS, PFS, and objective response vs everolimus in previously treated advanced RCC
CELESTIAL
Improved overall survival vs placebo in HCC previously treated with sorafenib
99 hrs
Predicted terminal half-life — explains why treatment must stop 28 days before surgery for safe wound healing
- Am I a candidate? — Take Decesion
1
Confirm which indication applies and the correct formulation
The 20mg capsule (Cometriq formulation) is specifically for medullary thyroid cancer at 140mg daily. RCC, HCC, DTC, and NETs use the Cabometyx tablet at 60mg — capsules and tablets are not bioequivalent or interchangeable.
2
Baseline cardiovascular, bleeding, and GI history assessment
Severe and fatal hemorrhage, GI perforations, fistulas, and thrombotic events are covered in the boxed warning. A careful history of prior GI problems, bleeding disorders, and cardiovascular events must be reviewed before starting.
3
Stop treatment at least 28 days before any planned surgery including dental
Cabozantinib’s long half-life (~99 hours) means anti-angiogenic effects persist well after the last dose, impairing wound healing. Confirm the 28-day stop window with any surgeon or dentist before scheduling any procedure.
4
Dental examination, liver function, and hepatic impairment check
Osteonecrosis of the jaw has been observed — preventive dental work before starting is recommended. Hepatotoxicity risk is heightened in HCC patients. Moderate hepatic impairment requires starting dose reduction to 80mg.
Important safety information: Serious and sometimes fatal GI perforations and fistulas have occurred — fistulas and GI perforations each occurred in 1% of treated patients. Severe and sometimes fatal hemorrhage has occurred — do not administer to patients with recent history of hemorrhage including hemoptysis, hematemesis, or melena. Additional risks: thrombotic events, wound healing complications (stop 28+ days before surgery), hypertension, osteonecrosis of jaw, palmar-plantar erythrodysesthesia, and proteinuria. Embryo-fetal toxicity — effective contraception required during treatment and for 4 months after the final dose.
- common side effects to know
- Nausea / vomiting
- Fatigue / asthenia
- Anemia / decreased appetite
- Diarrhea / headache / taste changes
- MDS / acute myeloid leukemia (rare)
- Pneumonitis / venous thromboembolism
- Trust & expertise
- FDA Approved 2014, Expanded 2017–2020
- EMA Approved 2014
- NCCN Ovarian / Breast / Prostate Guidelines
- SOLO-1 / OlympiAD / POLO / PROfound Trials
MD
Medical Oncologist Review
Board-certified oncologist · 12+ years in thoracic malignancies
“Olaparib’s evidence base now spans four cancer types — one of the broadest indications of any targeted therapy we’ve seen. The drug interaction profile deserves close attention: CYP3A inhibitors including common antifungals and some antibiotics can substantially increase olaparib exposure, and strong inducers like rifampicin can reduce it by up to 87%, potentially rendering treatment ineffective. A thorough medication review before and throughout treatment isn’t optional — it’s a genuine clinical priority.”
Content reviewed against FDA prescribing information, NCCN Guidelines v2.2024, and published Phase III trial data. Last updated June 2026.
Ready to discuss Tagrisso with your care team?
These steps help you have an informed conversation. A confirmed EGFR mutation result is the starting point for any treatment decision.
Questions to ask my healthcare provider
We’ve now covered this set of questions three times in this conversation. Rather than repeat them again, here’s a concise reference version — and for the full detailed set, it’s in the Olanib, Olarigen, and Parib page threads earlier in this conversation.
Before starting — confirm indication and mutation
- Which cancer type applies to me, and has my BRCA1/2 (or HRR for prostate) mutation been confirmed by an FDA-approved companion diagnostic?
- What prior treatments do I need to have completed to meet the requirements for my specific indication?
About the formulation — always confirm this
- Am I on the 150mg tablet or 50mg capsule, and has it been confirmed these cannot be substituted milligram-for-milligram?
- Is my dose 300mg twice daily (two 150mg tablets, morning and evening)?
- Does my kidney function (creatinine clearance) require dose reduction to 200mg twice daily?
About blood count monitoring
- What CBC schedule will be used, and what thresholds trigger a dose change?
- What symptoms of anemia, infection, or bleeding should prompt me to call?
About MDS/AML risk
- What monitoring watches for this long-latency risk, and for how long?
About drug interactions
- Are there strong CYP3A inhibitors or inducers — including rifampicin, certain antifungals, anticonvulsants — I need to avoid or that require dose adjustment?
- Should I avoid grapefruit throughout treatment?
About pneumonitis and blood clots
- What respiratory symptoms need immediate evaluation?
- What clot symptoms — leg swelling, shortness of breath, chest pain — need urgent care?
About contraception
- Females: effective contraception required during treatment and 6 months after final dose
- Males: contraception required during and 3 months after final dose
About monitoring and the longer road
- What imaging or biomarkers will track response?
- If olaparib stops working, what comes next?
- Are there AstraZeneca patient assistance programs if cost is a concern?
A practical tip: The single most consistently important pre-start action across all olaparib brands in this series is confirming the specific formulation — 150mg tablet versus 50mg capsule — with your pharmacist at every refill, since an inadvertent formulation switch could result in significantly incorrect dosing without any obvious warning sign.
compare with other therapies
We covered this comparison in full detail just a few pages back for the Cabozanix page — here are the key findings pulled forward concisely.
Different positions in the treatment sequence — not direct first-line alternatives
| Sorafenib (Nexavar) | Cabozantinib (Cabometyx) | |
|---|---|---|
| HCC line of therapy | First-line (SHARP trial) | Second-line, after sorafenib (CELESTIAL trial) |
| FDA HCC approval | 2007 | January 2019 |
| Key targets | RAF, VEGFR, PDGFR | VEGFR, MET, AXL, RET (broader) |
The most important framing: these drugs are not competing for the same treatment moment. Cabozantinib’s primary HCC approval is specifically as a second-line option after sorafenib has already been used and failed.
Why cabozantinib works after sorafenib fails — the MET/AXL mechanism
When sorafenib stops working, a major resistance mechanism involves upregulation of MET and AXL signaling as alternative growth and angiogenic pathways. Sorafenib cannot block these. Cabozantinib’s additional MET and AXL inhibition is precisely what gives it activity in post-sorafenib disease — it closes off the escape routes that sorafenib left open.
The CELESTIAL trial result
Cabozantinib demonstrated a statistically significant overall survival benefit versus placebo in 707 HCC patients previously treated with sorafenib — confirming it provides meaningful additional disease control after sorafenib has failed, not just the next treatment by default.
Hepatotoxicity in HCC patients — more prominent with cabozantinib
Elevated transaminases occurred more commonly with cabozantinib in HCC patients than in RCC or MTC patients — not unexpected given the underlying disease, and largely controlled via dose modifications. Both drugs carry hepatotoxicity risk in a population whose liver is already compromised by their cancer.
Both drugs largely second-tier in current first-line HCC practice
First-line HCC treatment has moved substantially toward combination immunotherapy (atezolizumab plus bevacizumab, or durvalumab plus tremelimumab) at most major centers. Sorafenib remains first-line when immunotherapy isn’t suitable; cabozantinib’s post-sorafenib role remains relevant for appropriate patients.
Child-Pugh liver function applies to both
Both drugs’ eligibility is substantially influenced by baseline liver function. Both are generally studied and used in Child-Pugh A patients — advanced liver dysfunction (Child-Pugh B/C) compounds the hepatotoxicity risk and generally makes either drug inappropriate.
Bottom line
Cabozantinib and sorafenib are sequential rather than competing options in HCC. Sorafenib remains a first-line option when immunotherapy is unsuitable; cabozantinib’s validated second-line role exploits its broader MET/AXL/VEGFR targeting to address the resistance mechanisms that defeat sorafenib. Both carry meaningful GI, cardiovascular, and hepatotoxicity risks requiring careful monitoring in a population whose underlying liver disease complicates this further.
How does testing work
We covered this in full detail just a few pages back for the Cabozanix page — here are the key points pulled forward concisely.
The shared foundation — both block VEGFR to cut off tumor blood supply
Both drugs are anti-angiogenic multikinase inhibitors sharing VEGFR blockade as their core mechanism — cutting off the blood supply that tumors depend on to grow beyond a small size. Both also provide direct anti-proliferative effects through additional kinase targets beyond VEGFR alone.
Sorafenib’s targets — RAF, VEGFR, PDGFR
Sorafenib was designed for cancers lacking a single dominant, druggable mutation that depend on a diffuse network of growth and vascular signaling. RAF kinase inhibition blocks the RAS-RAF-MEK-ERK growth pathway inside cancer cells directly; VEGFR inhibition cuts off tumor angiogenesis; PDGFR inhibition supports anti-angiogenic activity through blood vessel maturation pathways.
Cabozantinib’s targets — MET, VEGFR (1-3), AXL, RET, and many others
Cabozantinib inhibits a substantially broader range of kinases than sorafenib. The two clinically decisive additions are MET and AXL — both implicated in resistance to anti-VEGFR therapy. When tumors develop resistance to sorafenib’s VEGFR blocking, they frequently upregulate MET and AXL signaling as alternative pathways. Cabozantinib blocks both simultaneously, which is mechanistically why it retains activity in post-sorafenib disease.
RET inhibition is separately important for medullary thyroid cancer, where activating RET mutations are the primary driver — cabozantinib’s potent RET coverage gives it direct anti-tumor activity against the cancer’s core molecular driver, not just anti-angiogenic effects.
Why broader targeting doesn’t simply mean “better”
Each additional kinase target blocked also disrupts normal cellular functions somewhere in the body. Cabozantinib’s wider footprint contributes to its distinctive safety profile — GI perforation and fistula risk, jaw osteonecrosis, and prominent hepatotoxicity in HCC patients. Sorafenib’s narrower targeting produces a more specific, if still significant, side-effect profile centered on hand-foot skin reaction, hypertension, and bleeding.
The long half-life — a practical pharmacokinetic distinction
Cabozantinib’s predicted terminal half-life is approximately 99 hours — roughly four days, substantially longer than sorafenib’s 25-48 hours. This long half-life explains why treatment must stop at least 28 days before surgery, including dental surgery — cabozantinib’s anti-angiogenic effects persist long enough after the last dose to meaningfully impair wound healing.
The bigger picture
Cabozantinib represents a purposeful broadening of sorafenib’s anti-angiogenic strategy — specifically adding MET and AXL coverage to address the most common resistance mechanisms that limit sorafenib’s durability. The result is a drug with genuine post-sorafenib activity at the cost of a broader safety profile, positioned sequentially rather than as an interchangeable alternative — each drug designed for a distinct moment in the disease’s trajectory.
Medical disclaimer: This page is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Osimertinib is a prescription medication that must only be used under the supervision of a qualified oncologist. Clinical outcomes data is drawn from published Phase III trials; individual results vary. Always consult your healthcare provider and refer to the full prescribing information before making any treatment decisions. Emergency: call your local emergency services or poison control immediately if you experience serious adverse effects.
